Regulatory compliance – Page 55

Inspection readiness untested during FDA/EMA inspection – preventing escalation to warning letter

Ensuring Inspection Readiness to Prevent Escalations During FDA/EMA Inspections In today’s highly regulated pharmaceutical environment, maintaining inspection readiness is crucial. A lack of proper protocols can lead to serious consequences,…

Illegible entries in controlled records during deviation investigation – GDP remediation CAPA

Managing Illegible Entries in Controlled Records during Deviation Investigations Illegible entries in controlled records can significantly impact a pharmaceutical organization’s compliance with Good Documentation Practices (GDP) and data integrity standards,…

Inadequate evidence during inspection during WHO audit – question-and-answer handling techniques

In the highly regulated pharmaceutical industry, inadequate evidence during inspections, particularly during a WHO audit, can expose organizations to significant compliance risks. Such scenarios often lead to delays in approvals,…

Data attribution unclear during routine operations – ALCOA+ gap analysis

Addressing Data Attribution Challenges in Routine Operations: A Playbook for Pharmaceutical Professionals Data attribution unclear during routine operations is a pressing issue that can significantly impact regulatory compliance and data…

CAPA effectiveness doubted during dossier submission – documentation gaps reviewers flag

Enhancing CAPA Effectiveness for Dossier Submission: A Practical Playbook In the intricate world of pharmaceutical manufacturing, the effectiveness of the Corrective and Preventive Actions (CAPA) can often be scrutinized during…

Illegible entries in controlled records during inspection review – ALCOA+ gap analysis

Addressing Illegible Entries in Controlled Records for Regulatory Compliance Illegible entries in controlled records pose a significant challenge during inspection reviews, as they can undermine data integrity and compliance with…

PQ dossier deficiency during requalification – PQ assessment risk and mitigation

Strategies to Manage PQ Dossier Deficiencies During Requalification Efforts In the landscape of pharma manufacturing and quality compliance, deficiencies in the PQ (Prequalification) dossier during requalification can present significant challenges.…

Incomplete contemporaneous recording during inspection review – ALCOA+ gap analysis

Addressing Incomplete Recordings in Inspection Reviews: An ALCOA+ Playbook Incomplete contemporaneous recording during inspection reviews poses a significant risk to data integrity and regulatory compliance. The stakes are high; inadequate…

API change not reported during variation management – how to defend manufacturing readiness

“`html Defending Manufacturing Readiness After Unreported API Changes During Variation Management In the fast-paced world of pharmaceutical manufacturing, change management is crucial to maintaining regulatory compliance and ensuring product quality.…

Incomplete contemporaneous recording during deviation investigation – inspection citation risk and mitigation

Addressing Incomplete Documentation in Deviation Investigations: A Practical Playbook Incomplete contemporaneous recording during deviation investigations poses a significant risk in pharmaceutical manufacturing. This can lead to inspection citations, compromised data…

PQ dossier deficiency during dossier submission – PQ assessment risk and mitigation

Mitigating PQ Dossier Deficiencies During Submission: A Comprehensive Playbook In the landscape of pharmaceutical manufacturing, the accuracy and completeness of a Prequalification (PQ) dossier during submission is crucial for regulatory…

GDP errors in batch records during audit trail review – GDP remediation CAPA

Effective Strategies for Addressing GDP Errors in Batch Records During Audit Trail Reviews In the dynamic landscape of pharmaceutical manufacturing, the integrity of batch records is paramount. GDP errors identified…